Uripay
Generic Name
Solifenacin Succinate
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| uripay 100 mg tablet | ৳ 9.00 | ৳ 90.00 |
| uripay 200 mg tablet | ৳ 15.00 | ৳ 150.00 |
Description
Overview of the medicine
Uripay (Solifenacin Succinate) is a medication used to treat symptoms of an overactive bladder, such as urinary urgency, frequency, and incontinence (leakage). It belongs to a class of drugs called anticholinergics.
Uses & Indications
Dosage
Adults
The recommended starting dose is 5 mg once daily. If needed, the dose may be increased to 10 mg once daily.
Elderly
No dose adjustment is required for elderly patients. The recommended dose is 5 mg once daily, which may be increased to 10 mg once daily if needed.
Renal_impairment
In patients with severe renal impairment (creatinine clearance < 30 mL/min), the maximum dose should not exceed 5 mg once daily.
How to Take
Uripay tablets should be taken orally once daily with water. It can be taken with or without food. The tablet should be swallowed whole and not crushed or chewed.
Mechanism of Action
Solifenacin is a competitive muscarinic receptor antagonist. It works by blocking muscarinic receptors (primarily M3 receptors) in the bladder. This action inhibits the involuntary contractions of the detrusor muscle, increasing bladder capacity and reducing the symptoms of overactive bladder.
Pharmacokinetics
Onset
Initial effects within a few days; full therapeutic effect typically observed after 2-4 weeks of treatment.
Excretion
Eliminated predominantly via urine (approximately 50% as metabolites and less than 10% as unchanged drug) and feces (approximately 23%).
Half life
Approximately 45-68 hours, allowing for once-daily dosing.
Absorption
Well absorbed from the gastrointestinal tract, with absolute bioavailability of about 90%. Peak plasma concentrations are reached 3-8 hours after oral administration.
Metabolism
Extensively metabolized in the liver, primarily by the cytochrome P450 3A4 (CYP3A4) enzyme system.
Side Effects
Contraindications
- •Patients with urinary retention
- •Gastric retention
- •Uncontrolled narrow-angle glaucoma
- •Severe liver impairment
- •Patients undergoing hemodialysis
- •Hypersensitivity to the active substance or to any of the excipients
Drug Interactions
Other anticholinergic agents
Concomitant use with other anticholinergic agents may lead to more pronounced anticholinergic side effects.
Cholinergic receptor agonists
May reduce the effect of cholinergic receptor agonists.
CYP3A4 inhibitors (e.g., Ketoconazole)
Concomitant administration of solifenacin with strong CYP3A4 inhibitors (like ketoconazole) may significantly increase solifenacin exposure. The maximum dose of Uripay should not exceed 5 mg when co-administered with strong CYP3A4 inhibitors.
Drugs that stimulate gastrointestinal motility
Solifenacin may reduce the effect of drugs that stimulate gastrointestinal motility (e.g., metoclopramide, cisapride).
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include severe anticholinergic effects. Treatment should be symptomatic and supportive. Gastric lavage and activated charcoal may be considered. In case of severe anticholinergic effects, drugs like physostigmine or pilocarpine may be used under strict medical supervision.
Pregnancy & Lactation
Pregnancy: Category C. Use in pregnancy only if the potential benefit justifies the potential risk to the fetus. Lactation: It is unknown whether solifenacin is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months from the manufacturing date. Refer to the specific product packaging for exact shelf life.
Availability
Available in pharmacies nationwide
Approval Status
Approved by DGDA (Bangladesh)
Patent Status
Generic available
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
